PERBANDINGAN INDEKS ERITROSIT PADA PENDERITA TUBERKULOSIS YANG MENJALANI PENGOBATAN FASE AWAL DAN FASE LANJUTAN SEBAGAI MONITORING RISIKO ANEMIA
DOI:
https://doi.org/10.46356/jakk.v7i1.335Keywords:
Anemia, Anti- Tuberculosis, Drugs, Erythrocyte Indeks, TuberculosisAbstract
Tuberculosis is an infectious disease caused by the bacteria Mycobacterium tuberculosis. Tuberculosis can be treated by taking Anti-Tuberculosis Drugs (OAT). Tuberculosis treatment is divided into two phases, namely the initial phase and the advanced phase. Side effects of OAT use can cause hematological abnormalities in the blood such as anemia. The purpose of this study was to determine the comparison of erythrocytes in tuberculosis patients undergoing initial and advanced phase treatment as monitoring of anemia risk. This type of research was a comparative study. The research subjects were 30 subjects undergoing initial phase treatment and 30 subjects in advanced phase treatment obtained using the total sampling method. The results of this study obtained a normal erythrocyte index in the early phase of 21 (70%) subjects, normocytic hypochromic 6 (20%) subjects, and microcytic hypochromic 3 (10%) subjects. In comparison, the normal erythrocyte index in the advanced phase was 26 (87%) subjects and microcytic hypochromic 4 (13%) subjects. From the results of the statistical test study using the Mann-Whitney test, the Asymp. Sig. (2 tailed) value was obtained 0.000 (<0.05), which indicates that there is a comparison between the results of the erythrocyte index examination in TB patients undergoing early and advanced phase treatment so that in this study, the hypothesis H is accepted and Ho is rejected. This study concludes that more people experience anemia in the early phase of treatment than in the advanced phase of treatment.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Yanti Sunaidi, Imelda pongsimpin; Nuramaniyah Taufiq
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish on JAKK can share their research in a number of ways. JAKK does not impose an embargo on published journals, meaning that researchers can access it openly after the article is published. Researchers who have subscribed to access to articles can also share.
JAKK already uses the Open Journal System (OJS) thereby enabling the final version of all published research articles to be placed in any digital archive immediately after publication. JAKK can automatically make feeds of open access articles available to any repository that wishes to receive them.
Authors who publish with this journal agree to the following terms:
* Authors retain copyright and grant the journal right of first publication, with licensed under a Creative Commons Attribution ShareAlike 4.0 International License (CC BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
* Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
* Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.